PYLARIFY Makes History as First Blockbuster Radiodiagnostic Amid PSMA Market Expansion
PYLARIFY becomes first radiodiagnostic to exceed $1 billion in annual sales with 24% growth, as PSMA-targeted prostate cancer treatments gain significant market momentum.
NVSLNTHPET imagingPYLARIFY